Understanding the mechanisms of normal trafficking of A1AT across the endothelium, but also those underlying its disruption, may highlight new risk factors for CS-induced lung disease in both AATD and usual COPD, and may inform future strategies for A1AT supplementation. The gene discussed is SERPINA1; the disease is lung disorder.